Riskpilot← Back to searchSign inGet full accessStayble Therapeutics AB
ABActiveOrg 5590248372Lennart Torstenssonsgatan 6Research and experimental development on natural sciences and engineering · NACE 7210Est. 20152 employees
Revenue 2024
SEK 0
EBITDA margin
—
+47% vs 2023
Equity ratio
74.2%
Financial strength
Net profit 2024
SEK -12,4M
+48% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -12,6M | +47% |
| Net profit | SEK -12,4M | +48% |
| Total assets | SEK 9,3M | -57% |
| Equity | SEK 6,9M | -58% |
| Employees | 2 | — |
Legal name
Stayble Therapeutics AB
Org number
5590248372
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1 september 2015
Share capital
SEK 5 684 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas av Gerward, Andreas Nils Lennart i förening med en av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder Styrelsen ska bestå av 5 styrelseledamöter och 0 styrelsesuppleanter.
Company purpose
Aktiebolaget ska bedriva läkemedelsutveckling och medicinteknisk utveckling samt därmed förenlig verksamhet.
Address
Lennart Torstenssonsgatan 6
Email
andreas.gerward@stayble.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −14 925 | −12 140 | −24 796 | −23 954 | −12 646 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −148 |
| EBIT | −14 925 | −12 140 | −24 796 | −23 954 | −12 794 |
| Net financials | −728 | 50 | 271 | 24 | 376 |
| Profit before tax | −15 487 | −12 090 | −24 526 | −23 737 | −12 418 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −15 487 | −12 090 | −24 526 | −23 737 | −12 418 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 17 997 | 43 639 | 19 148 | 21 703 | 9 257 |
| Equity | 15 549 | 39 808 | 15 282 | 16 508 | 6 873 |
| Long-term debt | 1 044 | 850 | 850 | 850 | 850 |
| Short-term debt | 1 404 | 2 981 | 3 016 | 4 345 | 1 535 |
| Total debt | 2 448 | 3 831 | 3 866 | 5 195 | 2 385 |
EBITDA margin
-1264600000.0%
This company
15.8%
Market median
-8003797568% vs market
20202024
Equity ratio
74.2%
This company
38.2%
Market median
+94% vs market
20202024
Return on equity
-180.7%
This company
18.4%
Market median
-1082% vs market
20202024
Net profit margin
-1241800000.0%
This company
8.1%
Market median
-15330864298% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.35×
This company
0.62×
Market median
+44% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AN Chief Executive Officer | Chief Executive Officer | 2020 |
KI Chief Auditor | Chief Auditor | 2021 |
| Former (1) | ||
LG Chief Auditor | Chief Auditor | 2020 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Board of Directors | 2020 | |
| Chairman | 2022 | |
| Board of Directors | 2020 | |
| Board of Directors | 2020 | |
| Board of Directors | 2022 | |
| Former (3) | ||
| Board of Directors | 2020 – 2020 | |
| Chairman | 2020 – 2022 | |
| Board of Directors | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Stayble Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Andreas Nils Lennart Gerward | Chief Executive Officer | 0 companies |
| Leif Gunnar Bohman | Chief Auditor | 0 companies |
| Kristofer Ingmar Håkansson | Chief Auditor | 0 companies |
| Erik Myung-Jin Kinnman | Board of Directors | 0 companies |
| Olof Ulf Stefan Björklund | Chairman | 0 companies |
| Per Gunnar Fernström | Board of Directors | 0 companies |
| Jane Buus Laursen | Board of Directors | 0 companies |
| Pontus Göran Ottosson | Board of Directors | 0 companies |
| Eva Catharina Bäärnhielm Marklund | Chairman | 0 companies |
| Kjell Stefan Olmarker | Board of Directors | 0 companies |
| Nina Gudrun Christina Anstrén | Board of Directors | 0 companies |